Lantheus Holdings To Be Acquired By Curium For Up To $8 Bln

India, Aug. 3 -- Lantheus Holdings, Inc. (LNTH), announced on Monday that it has agreed to be acquired by Curium, a radiopharmaceutical company backed by CapVest Partners, in a deal valued at up to $8 billion.

The transaction is expected to be financed with a combination of debt and equity and is not subject to financing conditions.

Under the definitive agreement, Curium US will acquire all outstanding Lantheus shares for $102.50 per share in cash at closing, plus non-transferable Contingent Value Rights of up to $12.00 per share tied to commercial milestones through 2030.

The total consideration of up to $114.50 per share represents a 38% premium to Lantheus' 60-day volume-weighted average price, a 29% premium to its 30-day VWAP, and a ...